Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02687633
Other study ID # 15-000699
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date August 2017

Study information

Verified date April 2018
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators are running an intervention study for young children with Tuberous Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that may improve social and communication skills in children with TSC. Eligible families will have a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be available to attend the weekly intervention sessions at UCLA.

The intervention will focus on teaching caregivers skills to improve the social and communication outcomes of their children. The content of the intervention will be individually tailored to the child's developmental level. The intervention involves pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3 parent-child dyad and the curriculum focuses on improving social-communication and play skills.


Description:

Most children with Tuberous Sclerosis Complex (TSC) suffer from neurodevelopmental disabilities, including intellectual disability (ID) and autism spectrum disorder (ASD). There is a tremendous need for early intervention for all infants with TSC, with a focus on improving non-verbal cognition and social communication skills. However, no studies have investigated whether early intervention can improve social communication skills in infants with TSC. As a result, families of infants with TSC struggle to receive adequate interventions targeting these areas of development.

The investigators propose to enroll 32 infants and toddlers with TSC to study an evidence-based behavioral intervention in infants with TSC, combining the efforts of investigators with expertise in autism intervention, infant development, and TSC. The proposed intervention study adapts a parent-mediated treatment called JASPER (Joint attention, symbolic play, engagement, regulation) that has successfully improved social communication outcomes in toddlers and young children with ASD.

JASPER intervention will last 3 months, and is split into two phases. Phase 1 occurs for the first 2 weeks of intervention, and consists of daily 1 hour intervention sessions (Monday through Friday) for 2 weeks. After Phase 1, Phase two begins, and consists of 60 minute sessions once a week for 10 weeks. Participants will receive behavioral assessments and EEG across 4 assessment time points during this study: At the start of participation in the study, two weeks into participation of the study, 3 months into participation of the study, and 6 months into participation in the study. The behavioral assessments administered throughout these time points will measure social communication skills, overall cognitive functioning, and non-verbal communication. EEG is sensitive to subtle changes in the brain and may be able to capture responses to treatment prior to clinical or behavioral change, and can inform researchers of the brain basis for the behavioral changes found with intervention. The EEG at each time point will be 30-45 minutes in length, and will require the participant to be awake, as they will watch several short videos on a tv screen while recording EEG data.

There are 2 randomized participation groups in this study, Treatment Group 1, and Treatment Group 2. Treatment group 1 will begin JASPER intervention immediately, and thus will complete the first 3 assessment time points while in intervention, and the 4th assessment time point 3 months after intervention ends. Treatment Group 2 will complete the 4 assessment time points while receiving services as usual in the community, and will begin intervention after the 4th assessment time point. Treatment group 1 will participate in this study for a total of 6 months, and treatment group 2 will participate in the study for a total of 9 months, since they will receive services in the community as usual for 6 months before beginning the 3 month intervention. Group assignment is randomized, and each participant has an equal chance of being assigned to either treatment group.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 12 Months to 36 Months
Eligibility Inclusion Criteria:

- A confirmed diagnosis of Tuberous Sclerosis Complex

Exclusion Criteria:

- A mental age less than 6 months. A plan for epilepsy surgery during the study participation period.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
JASPER
JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.

Locations

Country Name City State
United States UCLA Semel Insitute Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Los Angeles Boston Children’s Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary change from baseline in Joint Engagement (shared engagement in a play routine) at 2 weeks into study participation, according to the parent caregiver interaction assessment. Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. 2 weeks
Primary change from baseline in Joint Engagement (shared engagement in a play routine) at 3 months into study participation, according to the parent caregiver interaction assessment. Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. 3 months
Primary change from baseline in Joint Engagement (shared engagement in a play routine) at 6 months into study participation, according to the parent caregiver interaction assessment. Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine. 6 months
Secondary Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 2 weeks ESCS (Early Social Communication Scales) Assessment. 2 weeks
Secondary Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 3 months ESCS (Early Social Communication Scales) Assessment. 3 months
Secondary Change from baseline in the amount of time spent in a Joint Attention (the coordination of attention between objects and people for the purpose of sharing) state at 6 months ESCS (Early Social Communication Scales) Assessment. 6 months
Secondary Change from baseline in Symbolic Play (types of play and level of play) at 2 weeks, according to the Structured Play Assessment (SPA) The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. 2 weeks
Secondary Change from baseline in Symbolic Play (types of play and level of play) at 3 months, according to the Structured Play Assessment (SPA) The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. 3 months
Secondary Change from baseline in Symbolic Play (types of play and level of play) at 6 months, according to the Structured Play Assessment (SPA) The Structured Play Assessment measures the child's play level, based on distinct sets of toys that target specific developmental markers of play. 6 months
Secondary Change from baseline at 3 months in developmental quotient, as determined by the Mullen Scales of Early Learning Cognition will be determined by a Developmental Quotient on a traditional cognitive measure, the Mullen Scales of Early Learning 3 months
Secondary Change from baseline at 6 months in developmental quotient, as determined by the Mullen Scales of Early Learning Cognition will be determined by a Developmental Quotient on a traditional cognitive measure, the Mullen Scales of Early Learning 6 months
Secondary Change from baseline at 2 weeks in the amount of Parent use of social communication support strategies Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. 2 weeks
Secondary Change from baseline at 3 months in the amount of Parent use of social communication support strategies Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. 3 months
Secondary Change from baseline at 6 months in the amount of Parent use of social communication support strategies Parent use of social communication support strategies as taught by JASPER will be measured by a parent-child interaction assessment. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02201212 - Everolimus for Cancer With TSC1 or TSC2 Mutation Phase 2
Completed NCT01767779 - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting NCT05104983 - Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Phase 2
Recruiting NCT02098759 - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex N/A
Recruiting NCT01730209 - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase 2/Phase 3
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT04987463 - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Phase 2/Phase 3
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Recruiting NCT06392009 - A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II Phase 1/Phase 2
Enrolling by invitation NCT05604170 - Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy Phase 3
Completed NCT03276195 - Studies in Patients With Tuberous Sclerosis Complex
Recruiting NCT05059327 - Basimglurant in Children, Adolescents, and Young Adults With TSC Phase 2
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT04112537 - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Active, not recruiting NCT02962414 - Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Phase 3
Active, not recruiting NCT05495425 - Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Phase 3
Active, not recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Completed NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study Phase 2
Recruiting NCT06160310 - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)